中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
—— | (4R*,5S*,6S*)-5,6-epoxy-4-hydroxy-2-(7-methyl-3-methylene-6-octene-1-ynyl)-2-cyclohexen-1-one | —— | C16H18O3 | 258.317 |
—— | (1S,5R,6R)-5-(tert-Butyl-dimethyl-silanyloxy)-3-(7-methyl-3-methylene-oct-6-en-1-ynyl)-7-oxa-bicyclo[4.1.0]hept-3-en-2-one | 180303-14-4 | C22H32O3Si | 372.58 |
—— | 5,5-Dimethoxy-4-(7-methyl-3-methylene-oct-6-en-1-ynyl)-7-oxa-bicyclo[4.1.0]hept-3-en-2-one | 190016-11-6 | C18H22O4 | 302.37 |
—— | 5,5-Dimethoxy-4-(7-methyl-3-methylene-oct-6-en-1-ynyl)-7-oxa-bicyclo[4.1.0]hept-3-en-2-ol | 190016-12-7 | C18H24O4 | 304.386 |
The epoxyquinol derivatives (–)-bromoxone acetate (ent-1) and (–)-tricholomenyn A (2) have been prepared from the cis-1,2-dihydrocatechols 3 and 4, respectively. Compounds 3 and 4 are themselves obtained in enantiomerically pure form through the whole-cell biotransformation of the corresponding halobenzene.
Palladium-catalyzed oxidative desymmetrization enables the efficient synthesis of both enantioenriched cycloalkenone building blocks and diverse epoxyquinoid natural products.